Every DEF 14A that iSpecimen Inc. (ISPC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ISPC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ISPC filings page.
iSpecimen Inc. revised the approval standard for Proposal No. 2, its proposed reverse stock split. The special meeting was convened October 9, 2026, and adjourned only on Proposal No. 2 to October 30, 2026, at 10:00 a.m. Eastern. Approval requires votes “FOR” to exceed votes “AGAINST”; abstentions and shares not voted have no effect. The company says it expects to meet Nasdaq’s minimum-holder requirement immediately after the split takes effect.
The proposal would authorize a 1-for-10 to 1-for-100 reverse split, with the exact ratio set by the board. Brokers may vote uninstructed street-name shares at their discretion. Stockholders may vote or change votes online or by phone through 11:59 p.m. Eastern on October 29, 2026, or at the adjourned meeting. Previously submitted votes remain valid unless properly revoked; the board unanimously recommends “FOR” Proposal No. 2.
iSpecimen Inc. (ISPC) is calling a virtual special meeting on October 9, 2026 to seek stockholder approval for several capital and strategic actions. Holders of 2,518,590 common shares as of August 12, 2026 may vote.
Proposal 1 would approve, under Nasdaq Listing Rule 5635(d), issuing more than 19.99% of pre‑May 8, 2026 shares in connection with a May 2026 PIPE, including full‑ratchet anti‑dilution and most‑favored‑nation adjustments to pre‑funded warrants. Proposal 2 would authorize, but not require, a reverse stock split between 1‑for‑10 and 1‑for‑100, following prior 1‑for‑20 (2024) and 1‑for‑40 (2026) splits, mainly to help maintain Nasdaq listing and increase available authorized but unissued shares.
Proposal 3 would pre‑approve future convertible or equity‑linked financings over the next 12 months at discounts up to 80% from the lowest VWAP, potentially causing substantial dilution. Proposal 4 seeks approval of a $4.5 million AI asset acquisition from Foldlab AI Ltd., paid as $2.0 million in milestones plus $2.5 million in stock locked in escrow for five years. Proposal 5 would allow adjournment to solicit more proxies if needed.
iSpecimen Inc. is asking stockholders to approve several items at its 2025 virtual annual meeting on December 31, 2025. Holders of common stock as of November 3, 2025, when 9,771,028 shares were outstanding, can vote online, by phone, or by mail.
Stockholders will vote on electing two Class I directors to three-year terms, ratifying Bush & Associates CPA LLC as independent auditor for 2025, and approving the new 2025 Stock Incentive Plan. The plan would reserve 1,000,000 shares of common stock for equity awards, supplementing the Amended and Restated 2021 Stock Incentive Plan, which had 73,084 shares available as of October 28, 2025. The board is also seeking authority to adjourn the meeting if needed and recommends voting “FOR” all proposals.